Dalargin: menopausal symptoms and six-month follow-up — RU2821826C1
Борис Юльевич Чебураков · 2024 · RU2821826C1 · patent family RU2821826C1
Published 2024-06-26.
Reported patent results
Reported findings
The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.
Patent report of 23 women aged 45–55: Dalargin n=15 versus saline placebo n=8, treated for 30 days in 2022–2024. Randomization and masking are not described.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported clinical improvement | 15/15 (100%) with Dalargin versus 5/8 (62.5%) with placebo | Broad symptom-based outcome; no prespecified responder threshold reported · After the 30-day course |
| Six-month follow-up | All 15 Dalargin recipients reportedly retained improvement; all 8 placebo recipients returned to baseline | Follow-up completeness and independent assessment not established · 6 months |
| Illustrative patient: hot flashes | 15–20/day at baseline, 3–5/day at day 15, absent at day 30 | One 54-year-old patient; not a group mean · Days 15 and 30; benefit reported at 6 months |
| Reported tolerability | No complications or side effects reported | Small patent series; systematic adverse-event ascertainment not described |
Unequal small groups, undefined improvement criteria, no documented allocation concealment or blinding, and no statistical estimates. These are inventor-reported observations, not established efficacy. The unrelated IPH GAA percentages are not Dalargin or Pineamin results.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. This 2024 patent reports a 23-woman comparison of Dalargin versus saline placebo. Pineamin is mentioned only as background, not as a tested combination.
The small unequal groups, undefined response criteria and unverified allocation and masking prevent an established treatment effect.
- Publication
- RU2821826C1 ↗ · 2024-06-26
- Earliest priority / filing
- Not established / 2024-04-13
- Original applicant / assignee
- Борис Юльевич Чебураков
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating climacteric syndrome in women
Inventors: Борис Юльевич Чебураков.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The small unequal groups, undefined response criteria and unverified allocation and masking prevent an established treatment effect.
- Unequal small groups, undefined improvement criteria, no documented allocation concealment or blinding, and no statistical estimates. These are inventor-reported observations, not established efficacy. The unrelated IPH GAA percentages are not Dalargin or Pineamin results.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-RU2821826C1. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Борис Юльевич Чебураков. Dalargin: menopausal symptoms and six-month follow-up — RU2821826C1 RU2821826C1 · patent family RU2821826C1 2024.
Molekul research summary: https://molekul.io/research/patent-ru2821826c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry